Mark Raffeld

45.6k total citations · 6 hit papers
428 papers, 27.4k citations indexed

About

Mark Raffeld is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Mark Raffeld has authored 428 papers receiving a total of 27.4k indexed citations (citations by other indexed papers that have themselves been cited), including 221 papers in Pathology and Forensic Medicine, 198 papers in Oncology and 111 papers in Genetics. Recurrent topics in Mark Raffeld's work include Lymphoma Diagnosis and Treatment (205 papers), Viral-associated cancers and disorders (111 papers) and Chronic Lymphocytic Leukemia Research (93 papers). Mark Raffeld is often cited by papers focused on Lymphoma Diagnosis and Treatment (205 papers), Viral-associated cancers and disorders (111 papers) and Chronic Lymphocytic Leukemia Research (93 papers). Mark Raffeld collaborates with scholars based in United States, Germany and Malaysia. Mark Raffeld's co-authors include Elaine S. Jaffe, Stefania Pittaluga, Lynn Sorbara, ES Jaffe, Liqiang Xi, Steven A. Rosenberg, Mark E. Dudley, Maryalice Stetler‐Stevenson, Wyndham H. Wilson and Richard M. Sherry and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Mark Raffeld

420 papers receiving 26.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

2002 2.2k citations Mark E. Dudley, John R. Wunderlich et al. profile →
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

2010 1.0k citations James N. Kochenderfer, Wyndham H. Wilson et al. Blood profile →
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma

2006 622 citations Mark Raffeld et al. profile →
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

2014 585 citations Paul F. Robbins, Sadik H. Kassim et al. Clinical Cancer Research profile →
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

2013 492 citations Robert O. Carpenter, Moses O. Evbuomwan et al. Clinical Cancer Research profile →
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma

2019 301 citations Richard A. Morgan, Richard M. Sherry et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Raffeld United States	90	14.1k	11.0k	7.8k	6.6k	5.5k	428	27.4k
Brunangelo Falini Italy	86	10.7k 0.8×	15.5k 1.4×	7.8k 1.0×	9.3k 1.4×	7.6k 1.4×	390	32.9k
Harald Stein Germany	56	8.3k 0.6×	10.0k 0.9×	4.7k 0.6×	4.3k 0.6×	3.9k 0.7×	218	20.4k
Stefano Pileri Italy	83	12.9k 0.9×	20.1k 1.8×	7.2k 0.9×	4.7k 0.7×	7.1k 1.3×	537	30.6k
Lawrence M. Weiss United States	82	10.2k 0.7×	9.1k 0.8×	3.4k 0.4×	3.7k 0.6×	2.8k 0.5×	373	23.9k
Stefania Pittaluga United States	81	9.8k 0.7×	10.0k 0.9×	4.6k 0.6×	2.8k 0.4×	4.6k 0.8×	399	19.9k
Georges Delsol France	69	9.6k 0.7×	14.6k 1.3×	4.3k 0.6×	3.5k 0.5×	4.7k 0.8×	272	21.5k
Andreas Rosenwald Germany	73	7.6k 0.5×	10.6k 1.0×	5.6k 0.7×	6.1k 0.9×	6.1k 1.1×	421	20.3k
Michael Hummel Germany	73	7.6k 0.5×	8.4k 0.8×	4.0k 0.5×	3.6k 0.5×	2.7k 0.5×	461	18.5k
Roger A. Warnke United States	79	9.1k 0.6×	11.2k 1.0×	5.9k 0.8×	2.9k 0.4×	4.3k 0.8×	280	20.9k
Wyndham H. Wilson United States	66	9.0k 0.6×	8.2k 0.7×	4.8k 0.6×	4.0k 0.6×	4.8k 0.9×	329	17.6k

Countries citing papers authored by Mark Raffeld

Since Specialization

Citations

This map shows the geographic impact of Mark Raffeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Raffeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Raffeld more than expected).

Fields of papers citing papers by Mark Raffeld

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Raffeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Raffeld. The network helps show where Mark Raffeld may publish in the future.

Co-authorship network of co-authors of Mark Raffeld

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Raffeld. A scholar is included among the top collaborators of Mark Raffeld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Raffeld. Mark Raffeld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ye, Peiying, Jenna Bergerson, Isaac Brownell, et al.. (2025). Resolution of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling. New England Journal of Medicine. 393(5). 469–478.

Xi, Liqiang, Trinh Pham, Eden C. Payabyab, et al.. (2016). Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma. Clinical Cancer Research. 22(22). 5480–5486. 77 indexed citations

Pittaluga, Stefania, Susan Price, Mark Raffeld, et al.. (2016). Bone marrow findings in autoimmune lymphoproliferative syndrome with germline FAS mutation. Haematologica. 102(2). 364–372. 13 indexed citations

Rothermel, Luke D., Arvind Sabesan, Daniel J. Stephens, et al.. (2015). Identification of an Immunogenic Subset of Metastatic Uveal Melanoma. Clinical Cancer Research. 22(9). 2237–2249. 64 indexed citations

Draper, Lindsey M., Mei Li M. Kwong, Alena Gros, et al.. (2015). Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clinical Cancer Research. 21(19). 4431–4439. 141 indexed citations

Dumitriu, Bogdan, Sawa Ito, Xingmin Feng, et al.. (2015). Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study. The Lancet Haematology. 3(1). e22–e29. 39 indexed citations

Gong, Shunyou, et al.. (2015). Epstein-Barr virus–associated inflammatory pseudotumor presenting as a colonic mass. Human Pathology. 46(12). 1956–1961. 24 indexed citations

Robbins, Paul F., Sadik H. Kassim, Thai L.N. Tran, et al.. (2014). A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. Clinical Cancer Research. 21(5). 1019–1027. 585 indexed citations breakdown →

Carpenter, Robert O., Moses O. Evbuomwan, Stefania Pittaluga, et al.. (2013). B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma. Clinical Cancer Research. 19(8). 2048–2060. 492 indexed citations breakdown →

10.

Tamburrino, Anna, Alfredo Molinolo, Paolo Salerno, et al.. (2012). Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases. Clinical Cancer Research. 18(13). 3532–3540. 60 indexed citations

11.

Kelly, Ronan J., Arun Rajan, Jeremy Force, et al.. (2011). Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib. Clinical Cancer Research. 17(5). 1190–1199. 58 indexed citations

12.

Kummar, Shivaani, Mark Raffeld, Lamin Juwara, et al.. (2011). Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors. Clinical Cancer Research. 17(15). 5123–5131. 100 indexed citations

13.

Ward, Yvona, Ross Lake, Juan Juan Yin, et al.. (2011). LPA Receptor Heterodimerizes with CD97 to Amplify LPA-Initiated RHO-Dependent Signaling and Invasion in Prostate Cancer Cells. Cancer Research. 71(23). 7301–7311. 133 indexed citations

14.

O’Mahony, Deirdre, John C. Morris, Maryalice Stetler‐Stevenson, et al.. (2009). EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies. Clinical Cancer Research. 15(7). 2514–2522. 35 indexed citations

15.

Killian, Jonathan Keith, Sven Bilke, Sean Davis, et al.. (2009). Large-Scale Profiling of Archival Lymph Nodes Reveals Pervasive Remodeling of the Follicular Lymphoma Methylome. Cancer Research. 69(3). 758–764. 36 indexed citations

16.

Feldman, Andrew L., Daniel A. Arber, Stefania Pittaluga, et al.. (2008). Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood. 111(12). 5433–5439. 221 indexed citations

17.

Beltaifa, Senda, et al.. (2008). Protracted haemangioblastic proliferation and differentiation in von Hippel–Lindau disease. The Journal of Pathology. 216(4). 514–520. 27 indexed citations

18.

Wilson, Wyndham H., Kieron Dunleavy, Stefania Pittaluga, et al.. (2008). Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. Journal of Clinical Oncology. 26(16). 2717–2724. 217 indexed citations

19.

Lorenzi, Philip L., William C. Reinhold, Martina Rudelius, et al.. (2007). Asparagine synthetase as a causal, predictive biomarker forL-asparaginase activity in ovarian cancer cells. Molecular Cancer Therapeutics. 5(11).

20.

Srivastava, Meera, Lukas Bubendorf, Mark Raffeld, et al.. (2004). Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients. Clinical Cancer Research. 10(7). 2344–2350. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact